JP5479337B2 - Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用 - Google Patents

Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用 Download PDF

Info

Publication number
JP5479337B2
JP5479337B2 JP2010520122A JP2010520122A JP5479337B2 JP 5479337 B2 JP5479337 B2 JP 5479337B2 JP 2010520122 A JP2010520122 A JP 2010520122A JP 2010520122 A JP2010520122 A JP 2010520122A JP 5479337 B2 JP5479337 B2 JP 5479337B2
Authority
JP
Japan
Prior art keywords
protein kinase
kinase inhibitor
additional embodiments
alkyl
mek
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010520122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535233A (ja
JP2010535233A5 (enExample
Inventor
マイナー，ジェフリー，エヌ．
チャップマン，マーク，エス．
クォルト，バリー
アジェイ，アレックス
ユー，チュンロン
Original Assignee
アルディア バイオサイエンス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Priority claimed from US12/016,897 external-priority patent/US7820664B2/en
Application filed by アルディア バイオサイエンス，インク． filed Critical アルディア バイオサイエンス，インク．
Publication of JP2010535233A publication Critical patent/JP2010535233A/ja
Publication of JP2010535233A5 publication Critical patent/JP2010535233A5/ja
Application granted granted Critical
Publication of JP5479337B2 publication Critical patent/JP5479337B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010520122A 2007-07-30 2008-07-28 Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用 Expired - Fee Related JP5479337B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 2007-07-30
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US12/016,897 2008-01-18
US12/016,897 US7820664B2 (en) 2007-01-19 2008-01-18 Inhibitors of MEK
PCT/US2008/071397 WO2009018238A1 (en) 2007-07-30 2008-07-28 Combinations of mek inhibitors and raf kinase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2010535233A JP2010535233A (ja) 2010-11-18
JP2010535233A5 JP2010535233A5 (enExample) 2011-09-22
JP5479337B2 true JP5479337B2 (ja) 2014-04-23

Family

ID=40304797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520122A Expired - Fee Related JP5479337B2 (ja) 2007-07-30 2008-07-28 Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用

Country Status (6)

Country Link
US (1) US8648116B2 (enExample)
EP (1) EP2175885B1 (enExample)
JP (1) JP5479337B2 (enExample)
CA (3) CA2924436A1 (enExample)
UA (1) UA99731C2 (enExample)
WO (1) WO2009018238A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CN101277720A (zh) * 2005-09-01 2008-10-01 卫材R&D管理有限公司 崩解性被改善的药物组合物的制备方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
KR20110014149A (ko) * 2008-04-14 2011-02-10 아디아 바이오사이언스즈 인크. 조성물 및 이것의 제조 및 사용 방법
CN102065859B (zh) * 2008-06-13 2012-10-03 诺瓦提斯公司 用于神经纤维瘤病的取代的苯并咪唑类
CA2738485A1 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CN103948600A (zh) * 2009-03-11 2014-07-30 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
TWI524890B (zh) 2009-07-24 2016-03-11 亞德生化公司 （ｒ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺及（ｓ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺之製備
HUE026957T2 (en) 2009-08-19 2016-07-28 Eisai R&D Man Co Ltd A pharmaceutical composition comprising a quinoline derivative
WO2011044072A1 (en) * 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
BR112012008599A2 (pt) 2009-10-13 2019-09-24 Allostem Therapeutics Llc composto da formula (i), composto da fórmula (ia), composto da fórmula (ic), composto da fórmula (ii), composto da fórmula (iia), composto, método para tratamento de um transtorno hiperproliferativo em um mamífero, que inclui um humano, método para tratamento de uma doença, condição ou transtorno inflamatório em um mamífero, que inclui um humano, método para tratamento de um transtorno ou condição que é modulada pela cascata de meik em um mamífero, que inclui um himano, método para tratar ou prevenir câncer, composição farmacêutica e método para inibir uma enzima mek
AU2010306653B2 (en) 2009-10-16 2013-10-24 Novartis Ag Combination
NZ599565A (en) 2009-11-04 2013-05-31 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
TW201802091A (zh) 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
ES2714875T3 (es) * 2010-03-09 2019-05-30 Dana Farber Cancer Inst Inc Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
PE20140165A1 (es) * 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
DE102011104267A1 (de) * 2011-06-06 2012-12-06 Philipps-Universität Marburg Verbindungen als PPAR beta/delta Inhibitoren für die Behandlung von PPAR beta/delta-vermittelten Erkrankungen
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
CA2838029A1 (en) * 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer
JPWO2013094546A1 (ja) * 2011-12-19 2015-04-27 住友化学株式会社 スルホン酸塩の製造方法
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
HK1206611A1 (en) * 2012-05-31 2016-01-15 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
CA2879252C (en) 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN107073121A (zh) * 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016078044A1 (zh) * 2014-11-19 2016-05-26 国防医学院 用于治疗癌症的药物组合物以及筛选药物的生物标记
CA2972189A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
KR102763349B1 (ko) 2015-02-25 2025-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
AU2017246452C1 (en) * 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
US11590133B2 (en) 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
EP3664808A1 (en) * 2017-08-11 2020-06-17 The Regents of The University of Michigan Inhibitors of mek/pi3k, jak/mek, jak/pi3k/mtor and mek/pi3k/mtor biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
AU2018319344B2 (en) 2017-08-23 2024-04-04 Cell Receptor AG Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3911329B1 (en) * 2019-06-18 2024-02-14 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en) 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
ES2175415T3 (es) 1996-07-18 2002-11-16 Pfizer Inhibidores de metaloproteasas matriciales basados en fosfinato.
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
PL348870A1 (en) * 1999-01-13 2002-06-17 Warner Lambert Co 1-heterocycle substituted diarylamines
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
DE602005013819D1 (de) * 2004-12-22 2009-05-20 Astrazeneca Ab Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel
PL1912636T3 (pl) * 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
MX2008013097A (es) * 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
CN101663279A (zh) * 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
US20110060049A1 (en) 2011-03-10
UA99731C2 (ru) 2012-09-25
CA2694646A1 (en) 2009-02-05
CA2694646C (en) 2017-09-05
CA2924418A1 (en) 2009-02-05
JP2010535233A (ja) 2010-11-18
WO2009018238A1 (en) 2009-02-05
EP2175885A4 (en) 2010-12-01
EP2175885A1 (en) 2010-04-21
EP2175885B1 (en) 2016-10-12
CA2924436A1 (en) 2009-02-05
US8648116B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
JP5479337B2 (ja) Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
JP6309880B2 (ja) Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
AU2013269809B2 (en) Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
JP2011518786A (ja) 調製及び使用のための組成物及び方法
US20190092724A1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
US20160271122A1 (en) Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
TWI481590B (zh) 作為ｍｅｋ抑制劑之ｎ－（芳胺基）磺醯胺（包括多晶型）衍生物及組合物，使用方法及其製備方法
TW201347752A (zh) 用於測定肝細胞腫瘤（ｈｃｃ）病患之治療有效反應之生物標記
HK1193032A (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
HK1193032B (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
HK1147396B (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140212

R150 Certificate of patent or registration of utility model

Ref document number: 5479337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees